The findings eventually led to the conclusion that radiotherapy is unable to improve the outcomes of PD-L1 and CTLA-4 combinative therapies in NSCLC sufferers resistant to PD-1 and PD-L1 therapies [254]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.